Study of Gelonin Purging of Autologous Stem Cells for Transplantation
Status:
Terminated
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
Patients with Acute Myelogenous Leukemia or Myelodysplastic are able to achieve a complete
remission but fail to achieve a prolonged disease-free survival. High dose chemotherapy and
autologous bone marrow transplantation has been shown to be effective in this group of
patients but hematopoietic recovery is slow, and infectious or bleeding complications are
common. The delay in hematopoietic recover is accentuated by the use of purging techniques.
This is a novel purging approach for autologous stem cell transplantation in patients with
Acute Myelogenous Leukemia or Myelodysplastic syndrome to allow for rapid engraftment with a
lower relapse rate therefore improving the therapeutic outcomes
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Busulfan Fludarabine Fludarabine phosphate GEL protein, Gelonium multiflorum Vidarabine